Drug Profile
Research programme: anti-RANKL monoclonal antibodies - Amgen
Alternative Names: AMG 161Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Amgen
- Class Monoclonal antibodies
- Mechanism of Action RANK ligand inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bone cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Bone-cancer in USA (Parenteral)
- 09 Oct 2009 Preclinical trials in Bone cancer in USA (Parenteral)